Literature DB >> 217440

Enzymic effects of beta-glucosidase destruction in mice. Changes in glucuronidase levels.

A Hara, N S Radin.   

Abstract

1. The injection into mice of a single dose of conduritol B epoxide, a covalent inhibitor of glucosidases, quickly produced changes in tissue levels of beta-D-glucuronidase (EC 3.2.1.31). The specific activity of the enzyme decreased in liver, spleen and kidney while brain showed little change. The inhibitor did not act on glucuronidase in vitro, so the effect of the inhibitor is complex, possibly a result of the loss of glucosidase activity. Since glucuronidase contains glucose, we suggest that the transport of the enzyme between subcellular regions and tissues involves loss of part of the glucose moieties. 2. Levels of glucocerebrosidase (D-glucosyl-N-acylsphingosine glucohydrolase, EC 3.2.1.45) dropped very rapidly after epoxide injection, reaching a minimum at 1 h in liver. There was a noticeable restoration of activity within the next 1--2 h. Aryl beta-glucosidase (EC 3.2.1.21) decrease somewhat less than cerebrosidase, reaching a minimum within 2 h. It too showed some recovery of activity within 3 h. 3. Acid phosphatase rose slightly in liver but not in brain. alpha-L-Fucosidase and angiotensin-converting enzyme were not affected by the epoxide injection. The latter two enzymes are known to contain glucose. 4. Injection of a hemolyzing agent, phenylhydrazine, produced an increased level of glucuronidase in liver and spleen within 6 days, but not in kidney. This enhancement was a little less in mice previously injected with the glucosidase inhibitor. 5. Mice injected with the epoxide once a day eight times showed a distinct rise in brain glucuronidase level, as well as a rise in brain weight. However, the other organs showed only the same decrease in glucuronidase specific activity noted with the single injection protocol. It is suggested that the difference is due to the blood-brain barrier, which could slow the loss of brain glucuronidase from the extracellular fluid.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 217440     DOI: 10.1016/0304-4165(79)90134-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Glucosylceramide and the level of the glucosidase-stimulating proteins.

Authors:  S C Datta; N S Radin
Journal:  Lipids       Date:  1986-11       Impact factor: 1.880

2.  Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease.

Authors:  W M Holleran; E I Ginns; G K Menon; J U Grundmann; M Fartasch; C E McKinney; P M Elias; E Sidransky
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

Review 3.  Glucosylceramide in the nervous system--a mini-review.

Authors:  N S Radin
Journal:  Neurochem Res       Date:  1994-05       Impact factor: 3.996

4.  Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.

Authors:  M Elleder
Journal:  J Inherit Metab Dis       Date:  2006-11-02       Impact factor: 4.982

5.  Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.

Authors:  You-Hai Xu; Rachel Reboulet; Brian Quinn; Joerg Huelsken; David Witte; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

6.  Stimulation of liver growth and DNA synthesis by glucosylceramide.

Authors:  S C Datta; N S Radin
Journal:  Lipids       Date:  1988-05       Impact factor: 1.880

7.  Glucosylceramides stimulate murine epidermal hyperproliferation.

Authors:  N L Marsh; P M Elias; W M Holleran
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

8.  Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish.

Authors:  Marta Artola; Chi-Lin Kuo; Lindsey T Lelieveld; Rhianna J Rowland; Gijsbert A van der Marel; Jeroen D C Codée; Rolf G Boot; Gideon J Davies; Johannes M F G Aerts; Herman S Overkleeft
Journal:  J Am Chem Soc       Date:  2019-03-04       Impact factor: 15.419

9.  In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.

Authors:  Chi-Lin Kuo; Wouter W Kallemeijn; Lindsey T Lelieveld; Mina Mirzaian; Iris Zoutendijk; Ayelet Vardi; Anthony H Futerman; Annemarie H Meijer; Herman P Spaink; Herman S Overkleeft; Johannes M F G Aerts; Marta Artola
Journal:  FEBS J       Date:  2019-02-02       Impact factor: 5.542

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.